{"id":"replacement-with-zonisamide","safety":{"commonSideEffects":[{"rate":"17","effect":"Somnolence"},{"rate":"13","effect":"Ataxia"},{"rate":"13","effect":"Dizziness"},{"rate":"13","effect":"Anorexia"},{"rate":"10","effect":"Headache"},{"rate":"9","effect":"Nausea"},{"rate":"8","effect":"Cognitive dysfunction"},{"rate":"1-4","effect":"Nephrolithiasis"},{"rate":"1-2","effect":"Hypohidrosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zonisamide inhibits voltage-gated sodium channels and T-type calcium channels, stabilizing neuronal membranes and reducing repetitive neuronal firing. It also has weak carbonic anhydrase inhibitory activity. These combined effects suppress seizure propagation and reduce the frequency of seizure episodes.","oneSentence":"Zonisamide is an anticonvulsant that blocks sodium and calcium channels in neurons, reducing abnormal electrical activity in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:08.691Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial seizures (adjunctive therapy)"},{"name":"Generalized tonic-clonic seizures (adjunctive therapy)"},{"name":"Lennox-Gastaut syndrome (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT01630057","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2009-09","conditions":"Partial Seizures","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Replacement with Zonisamide","genericName":"Replacement with Zonisamide","companyName":"Eisai Inc.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zonisamide is an anticonvulsant that blocks sodium and calcium channels in neurons, reducing abnormal electrical activity in the brain. Used for Partial seizures (adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy), Lennox-Gastaut syndrome (adjunctive therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}